Expert Solution Preview

Introduction:

Comparing the cost of treating infectious diseases in different countries can be a useful way to explore the economic burden of these diseases. This question asks us to consider the cost of treating infectious diseases in the United States compared to the cost in the United Kingdom, specifically in terms of person, time, and place. We will also discuss whether the economic cost is justified.

Answer:

Research suggests that the United States spends significantly more on healthcare than the United Kingdom, although the two countries have different healthcare systems and approaches to funding. According to a report from the Commonwealth Fund, the United States spends more than twice as much per capita on healthcare as the United Kingdom, with healthcare costs in the United States accounting for almost 18% of GDP (Gross Domestic Product) compared to less than 10% in the United Kingdom.

Research also shows that infectious diseases pose a significant economic burden on both countries, with costs associated with hospitalization, treatment, and lost productivity. According to Health System Tracker, the United States spends the most on infectious diseases, particularly on pneumonia and septicemia, followed by the UK, which spends the most on respiratory infections and vaccine-preventable diseases.

When considering the cost of treating infectious diseases in terms of person, it is important to note that the United States has a larger population than the United Kingdom, which means that the per capita cost of treating infectious diseases may be higher in the United States. In terms of time, research suggests that both countries have seen an increase in the economic burden of infectious diseases over the last few decades, although the rate of increase has been higher in the United States. In terms of place, research shows that the distribution of infectious diseases varies by location, with some areas having higher rates of infection than others.

Determining whether the economic cost of treating infectious diseases is justified is a complex issue that requires consideration of a variety of factors. Some argue that the cost of healthcare is necessary to provide high-quality treatments and prevent the spread of infectious diseases. Others argue that the high cost of healthcare in the United States is unsustainable and that there may be more cost-effective ways to prevent, diagnose, and treat infectious diseases. Ultimately, determining the economic cost of treating infectious diseases will require ongoing research, careful analysis, and thoughtful consideration of the broader societal and economic implications of healthcare policy and practice.